On June 21, 2012, Yamamoto, Shuji; Ohta, Hiroshi; Abe, Kumi; Araki, Yuko; Moriya, Minoru; Sun, Xiang-Min; Yasuhara, Akito published a patent.Recommanded Product: 386704-04-7 The title of the patent was Preparation of imidazolidin-2-one derivatives for inhibiting glycine transporter. And the patent contained the following:
Title compounds I [R1 = Ph, pyridyl, pyridazyl, etc. (herein, Ph, pyridyl and pyridazyl are optionally substituted with group 1); group 1 = alkyl, haloalkyl, alkoxy, etc.; R2 = Ph (optionally substituted with group 2) or mono- or bi-cyclic heteroaryl (optionally substituted with group 2); group 2 = Ph, alkyl, haloalkyl, etc.; R3, R4 = H, alkyl, cycloalkyl, etc.; R3 and R4, together with the carbon atom to which they are attached, may combine to form a cycloalkane, THF or tetrahydropyran; with a proviso that R3 and R4 cannot be hydrogen atom simultaneously; R5, R6 = H or alkyl; or pharmaceutically acceptable salts thereof] were prepared For example, to a solution of 3-(6-methoxypyridin-3-yl)-1,3-diazaspiro[4.5]decan-2-one (100 mg) in DMF (2 mL) was added NaH (23 mg), the resulting mixture was stirred for 30 min and treated with 5-(chloromethyl)-3-phenyl-1,2-oxazole (110 mg) at room temperature overnight to give, after work-up, compound II (109 mg). In glycine uptake inhibition assay, IC50 of III was 0.038 μM. Compounds I are claimed useful for the treatment of schizophrenia, Alzheimer disease, depression, etc. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Recommanded Product: 386704-04-7
The Article related to imidazolidinone preparation glycine transporter inhibitor, schizophrenia alzheimer disease depression treatment imidazolidinone glycine transporter inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Recommanded Product: 386704-04-7
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts